The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
Mirati’s Kras inhibitor looks better than Amgen’s on efficacy, but toxicity worries prevent a knockout punch.
Moderna battles Pfizer/Biontech to generate the first pivotal study data for a Covid-19 vaccine.
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
An attempt to abrogate the placebo response does not seem to have gone as planned.
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.